AINDEX
Markets

Precision BioSciences, Inc. (DTIL)

DTILNASDAQ-CMBiotechnology: Biological Products (No Diagnostic Substances)

$6.90

-0.3800 (-5.22%) today

Regular session, Nov 17, 10:47 AM ET

-5.22% 1D
Market cap
$263.08m
P/E
–
EPS, last 4 quarters
$-1.34
Dividend yield
–
Day range
$6.90 to $7.46
52-week range
$3.53 to $11.29
Average volume
–
Previous close
$7.28

Analysts

3 covering

Buy3 buy, 0 hold, 0 sell

Targets a year out average $40.00, +479.7% from here

$20.00now $6.90$60.00

Earnings

next estimate $-0.9000

Next report

Dec 2025

+271.4%

Mar 2026

-25.9%

Jun 2026

+4.0%

Sep 2026

+36.3%

estimate reported, and the surprise

Financials

QuarterDec 2025Mar 2026Jun 2026Sep 2026
Revenue$34.20m$10.84m––
Gross profit$34.20m$10.84m––
Operating income$12.51m-$9.07m-$19.16m-$20.43m
Net income$20.13m-$18.44m-$32.65m-$7.59m

News

8 latest

The company

Precision is a clinical stage gene editing company dedicated to improving life (DTIL) with its novel and proprietary ARCUS genome editing platform that differs from other technologies in the way it cuts, its smaller size, and its simpler structure. Key capabilities and differentiating characteristics may enable ARCUS nucleases to drive more intended, defined therapeutic outcomes. Using ARCUS, Precision's pipeline is comprised of in vivo gene editing candidates designed to deliver lasting cures for the broadest range of genetic and infectious diseases where no adequate treatments exist.

Sector
Health Care
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
Exchange
NASDAQ-CM
Region
North America

Often looked at with it

Figures from Yahoo, Nasdaq (Zacks consensus) and Lighter. Stocks can be minutes behind. Nothing here is advice.